GlassScriptPhysician profile
Sam Baroudi
NPI 1316936933
$3,623.58
in general payments reported to CMS, 2019-2025
34 companies · $293 in 2025
The $293 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $716 · 2020: $423 · 2021: $837 · 2022: $628 · 2023: $471 · 2024: $256 · 2025: $293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,020.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,019.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $630.13 | 2021-2025 | Ubrelvy, Dalvance |
| Novartis Pharmaceuticals Corporation | $434.79 | 2019-2025 | |
| Amgen INC. | $378.57 | 2019-2025 | Evenity, Prolia, Otezla |
| Novo Nordisk INC | $279.26 | 2019-2025 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $264.70 | 2019-2025 | Airsupra |
| Glaxosmithkline, LLC. | $239.18 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $186.46 | 2019-2023 | |
| Nevro Corp. | $103.00 | 2022-2023 | Senza |
| Lilly USA, LLC | $100.74 | 2023-2024 | Mounjaro, Jardiance |
| Astellas Pharma US INC | $98.44 | 2020-2024 | Veozah |
| Janssen Pharmaceuticals, INC | $80.26 | 2019-2023 | Xarelto |
| Boston Scientific Corporation | $74.11 | 2024 | Wavewriter Alpha Prime 16 |
| Allergan, INC. | $71.50 | 2020 | |
| Tactile Systems Technology INC | $71.32 | 2021-2025 | Nimbl, Flexitouch Plus |
| Sunovion Pharmaceuticals INC. | $64.93 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $62.91 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $61.49 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $51.62 | 2019-2022 | |
| Lucid Diagnostics INC. | $37.38 | 2023 | |
| Seqirus USA INC | $34.32 | 2022-2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Mannkind Corporation | $32.04 | 2019-2022 | |
| Amarin Pharma, INC. | $31.02 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $26.06 | 2023 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $25.27 | 2022 | |
| Dexcom, INC. | $25.07 | 2021 | |
| Abbott Laboratories | $23.41 | 2023 | Octrode |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.21 | 2022 | |
| Merck Sharp & Dohme LLC | $21.02 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $20.18 | 2023 | Lifevest |
| Philips North America LLC | $15.77 | 2024 | (Ck7) Extended Holter |
| Teva Pharmaceuticals USA, INC. | $15.29 | 2019 | |
| Topcon Healthcare Solutions, INC. | $14.99 | 2020 | |
| Sanofi-Aventis U.S. LLC | $14.86 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sam Baroudi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.